Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Citius Oncology, Inc. (NASDAQ: CTOR)
CTOR Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-8.10%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
284.90%
CTOR Stock Analysis
CTOR
PE Ratio:
CTOR
PEG Ratio:
Not Available
CTOR
Forward EPS Growth (12 month):
0.00%
CTOR
PS Ratio:
12.9
CTOR
PSG Ratio:
Not Available
CTOR
Forward Revenue Growth (12 month):
0.00%
CTOR Articles
No data was found